‘Anti-malaria drug can kill coronavirus’: Novartis chief
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus and has donated 130 million doses as part of the pandemic response.
This content was published on
3 minutes
swissinfo.ch/mga
Español
es
Medicamento antimalaria puede matar al coronavirus
“Pre-clinical studies in animals as well as the first data from clinical studies show that hydroxychloroquine kills the coronavirus,” Novartis Chief Executive Vas Narasimhan told the SonntagsZeitung newspaperExternal link on March 29.
On April 3, Novartis said it was donating a “considerable amount” of the drug to the Swiss authorities, which would organise distribution to hospitals. Switzerland is thus the first European country – and second country in the world after the US – to receive some doses.
Hydroxychloroquine, produced by Novartis’s Sandoz division among other companies, is also used to treat lupus and arthritis. “We are working with Swiss hospitals on possible treatment protocols for the clinical use of this drug [against Covid-19], but it is too early to say anything definitive,” added Narasimhan.
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of Covid-19.
Novartis had previously issued a pledgeExternal link to give away 130 million doses of the drug, including 50 million 200 gram doses it already has stockpiled. It has been reported that the United States has accepted 30 million doses.
“Novartis will work with stakeholders including the World Health Organization to determine the best distribution of the medicine to ensure broad access to patients most in need of this medicine globally,” the company stated on March 20.
Working with the US
Other Novartis drugs are also being explored as possible treatment for Covid-19 including the multiple sclerosis drug Gilenya and the cancer drug Jakavi, Narasimhan told the paper.
The Swiss drugmaker said on March 20 it was working with the US Food and Drug Administration (FDA) and the US government to initiate a phase 3 trial to evaluate the safety of the drug used to treat cytokine release syndrome and rheumatoid arthritis, two inflammatory diseases.
Decree
On April 3 Switzerland sought to speed access to drugs that could be used against Covid-19 with an order that allows them to be deployed in hospitals before getting formal approval by the country’s regulator.
The decree covers generic malaria medicine hydroxychloroquine, Abbvie’s HIV drug Kaletra, Gilead Science’s experimental remdesivir and Roche’s Actemra, all of which are being studied for potential use against coronavirus.
Swissmedic, responsible for vetting drugs in the country, also will get new powers to approve deviations from some legal requirements for medicines under review, the government said.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss climate activists block vehicles near Gotthard tunnel
This content was published on
Around ten climate activists briefly blocked the A2 motorway near the northern entrance of the Gotthard tunnel on Thursday.
Watches belonging to Michael Schumacher up for auction
This content was published on
Schumacher's family is auctioning off eight rare watches from his collection in Geneva. The Christie's auction will take place on Monday.
Joya Marleen and Baschi named best solo acts at Swiss Music Awards
This content was published on
St. Gallen singer Joya Marleen and Baschi from Basel were named artists of the year at the Swiss Music Awards 2024 on Wednesday night.
Swiss authorities announce cost-cutting in asylum sector
This content was published on
The government notably wants to improve integration into the labour force, particularly for people with protection status S.
Various leaders confirm participation at Ukraine peace conference
This content was published on
The presidents of Poland, Finland, and Latvia and the prime ministers of Spain and Belgium will be at the Swiss-hosted talks in mid-June.
This content was published on
In the winter season up to April 2024, railway and cable car operators ferried 3% more visitors compared to the previous winter, and 5% more than the five-year average.
Rhine flooding: Swiss to invest CHF1 billion with Austria
This content was published on
As part of an international agreement with Austria, the Swiss government wants to pump CHF1 billion ($1.1 billion) into flood protection measures along the Rhine over the next three decades.
Swiss government proposes CHF10 million UNRWA donation
This content was published on
After months of debate, Switzerland plans to give CHF10 million ($11 million) to the UN agency this year, rather than the CHF20 million initially foreseen.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis steps up coronavirus fight as part of new collaboration
This content was published on
Several big pharmaceutical companies have joined forces with the Bill & Melinda Gates Foundation in response to the coronavirus pandemic.
Swiss doctors call for better supplies of vaccines
This content was published on
Carlos Quinto, a board member of the Swiss Medical AssociationExternal link (FMH), told the Swiss public broadcaster SRFExternal link that stocks of Pneumovax, which helps patients with respiratory diseases or immune deficiencies to ward off pneumonia, have run out. “Patients are calling us and we then have to tell them that there is nothing left,”…
Who decides who gets access to the silver bullet to Covid-19?
This content was published on
Our regular analysis of what the biggest global companies in Switzerland are up to. This week: multinationals confront national interests.
WHO and Roche launch trials of potential coronavirus treatments
This content was published on
Roche is launching a clinical trial of a potential new Covid-19 drug, adding to rapidly growing investments in combating coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.